Tetrahydroaminoacridine‐induced ribosomal changes and inhibition of protein synthesis in rat hepatocyte suspensions
Marc W. Fariss, Sharon A. Johnsen, Lloyd P. Walton, Virgil R. Mumaw, Sidhartha D. Ray – 1 July 1994 – Tacrine (tetrahydroaminoacridine) is currently the only drug approved for the treatment of Alzheimer's disease. Unfortunately, tetrahydroaminoacridine therapy is often limited by this drug's propensity to induce reversible hepatotoxicity.